One of Wall Street’s top firms just gave a thumbs-up to Zoetis (NYSE:ZTS) stock. Citi initiated coverage with a Buy rating and a $145 price target, naming it the firm’s top pick in the animal health group. The thesis is straightforward: people treat their animals like family.
The initiation is part of a broader sector launch. Citi launched coverage of the animal health and dental sectors with a “cautiously optimistic” view, also initiating on Elanco Animal Health (NYSE:ELAN), IDEXX Laboratories (NASDAQ:IDXX), and Phibro Animal Health (NASDAQ:PAHC) simultaneously. Among the group, Zoetis stands out as Citi’s clearest conviction play.
| Ticker | Company | Firm | Action | Old Rating | New Rating | Old Target | New Target |
|---|---|---|---|---|---|---|---|
| ZTS | Zoetis | Citi | Initiation / Top Pick | N/A | Buy | N/A | $145 |
The Analyst’s Case
Citi’s thesis rests on the “humanization” of pets. The firm says the humanization pet trend is real and should drive more spending, a view supported by data showing nearly 40% of dogs of any age or size may be affected by OA pain and up to 40% of all cats have clinical signs of OA. That’s a massive addressable market for Zoetis’s pain management portfolio.
Citi also opened an “upside 90-day catalyst watch” on Zoetis, saying Solensia will return to growth in fiscal 2026. That’s a specific near-term signal worth watching, especially since U.S. mAb products including Librela and Solensia declined in Q4 2025.
Company Snapshot
Zoetis is the world’s largest producer of medicine and vaccinations for pets and livestock, with FY2025 revenue of $9.467 billion and a market cap of roughly $51 billion. Its companion animal segment generated $1.601 billion in Q4 2025 revenue, growing 2% year over year.
The pipeline strengthens the story. Zoetis received regulatory approvals for long-acting OA pain products Lenivia and Portela in Canada and the EU, with commercial launches expected in 2026. CEO Kristin Peck asserted, “Advancing our innovative pipeline is central to our strategy, and we achieved key milestones in 2025, including the first regulatory approvals for long-acting OA pain products Lenivia and Portela.”
Why the Move Matters Now
ZTS stock has declined 4% year to date and currently trades at around $121 against a recent high of $170.33. That pullback makes Citi’s initiation timely: the stock’s valuation has compressed while the underlying business keeps beating estimates.
Zoetis beat earnings expectations in all four quarters of 2025, and management guided for FY2026 adjusted diluted EPS of $7.00 to $7.10. The forward P/E ratio P/E ratio of 17x looks reasonable for a company with durable category leadership and a growing biologics pipeline.
What It Means for Your Portfolio
If you believe pet humanization is a lasting cultural shift, Zoetis stock offers a direct way to invest in that trend through a company with proven brand equity and a growing pipeline. The Solensia recovery thesis Citi flagged gives investors a specific near-term catalyst to monitor.
The risks remain real, however. Zoetis’s China revenue declined 23% in Q4 2025, foreign exchange headwinds persist, and tariff uncertainty clouds the 2026 outlook. Watch for whether Solensia and Librela regain U.S. momentum before sizing up a position.
Top Gaining Stocks
Top Losing Stocks